Feng Xuqin, Wang Qian
Department of Oncology, Nanchong Central Hospital, The Second Clinical College of North Sichuan Medical College, Nanchong, 637000, Sichuan, China.
Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.
Discov Oncol. 2024 Oct 14;15(1):555. doi: 10.1007/s12672-024-01404-3.
Keratin-15 (KRT15) involves in the progression and owns prognostic values in several solid cancers, whose clinical role in epithelial ovarian cancer (EOC) is rarely reported. This study aimed to identify the association of KRT15 expression with tumor features and survival of surgical EOC patients.
Formalin-fixed paraffin-embedded tumor tissues of 140 EOC patients who underwent tumor resection were retrieved for KRT15 determination using immunohistochemistry (IHC) assay.
The median (interquartile range) KRT15 IHC score was 0.0 (0.0-1.0), ranging from 0.0 to 12.0. Among all, 36.4% of patients had positive KRT15 expression (IHC score > 0) and 15.0% of patients had high KRT15 expression (IHC score > 3). KRT15 was positively related to lymph node metastasis incidence (P = 0.027), and showed a tendency to correlate to FIGO stage but without statistical significance (P = 0.052), while it was not correlated with age, other tumor features, and tumor markers. Positive KRT15 expression was linked with poor disease-free survival (DFS) (P = 0.009) and overall survival (OS) (P = 0.032). Notably, high KRT15 expression showed an even stronger relationship with worse DFS (P = 0.001) and OS (P < 0.001). After adjustment of multivariable Cox's regression, high KRT15 expression was independently correlated with unfavorable DFS (hazard ratio (HR): 2.241, P = 0.007).
Even though KRT15 is insufficiently expressed in EOC tissues generally, its positive expression or high expression can predict the lymph node metastasis and poor survival prognosis in EOC patients who undergo tumor resection.
角蛋白15(KRT15)参与多种实体癌的进展并具有预后价值,其在上皮性卵巢癌(EOC)中的临床作用鲜有报道。本研究旨在确定KRT15表达与手术治疗的EOC患者肿瘤特征及生存情况之间的关联。
收集140例行肿瘤切除术的EOC患者的福尔马林固定石蜡包埋肿瘤组织,采用免疫组织化学(IHC)检测法测定KRT15。
KRT15 IHC评分的中位数(四分位间距)为0.0(0.0 - 1.0),范围为0.0至12.0。其中,36.4%的患者KRT15表达阳性(IHC评分>0),15.0%的患者KRT15高表达(IHC评分>3)。KRT15与淋巴结转移发生率呈正相关(P = 0.027),与国际妇产科联盟(FIGO)分期有相关趋势但无统计学意义(P = 0.052),而与年龄、其他肿瘤特征及肿瘤标志物无关。KRT15阳性表达与无病生存期(DFS)差(P = 0.009)和总生存期(OS)差(P = 0.032)相关。值得注意的是,KRT15高表达与更差的DFS(P = 0.001)和OS(P < 0.001)关系更强。经多变量Cox回归调整后,KRT15高表达与不良DFS独立相关(风险比(HR):2.241,P = 0.007)。
尽管KRT15在EOC组织中总体表达不足,但其阳性表达或高表达可预测接受肿瘤切除术的EOC患者的淋巴结转移及不良生存预后。